Delving into the Thyrointegrin Antagonist & Cancer Therapeutics

Time: 3:40 pm
day: Day One


  • Considering the challenges in developing novel strategies and the failure of previous avb3 antagonists in cancer therapy
  • Pinpoint the problems with these in order to re-assess the MoAs
  • Overcome these challenges to design novel therapeutics